Experimental drug combo targets Hard-to-Treat HER2 cancers
NCT ID NCT07137416
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgically removed. Pidnarulex is an enzyme blocker that kills cancer cells, while trastuzumab deruxtecan is a targeted therapy that delivers chemotherapy directly to HER2-positive cells. The goal is to find a tolerable dose and see early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pidnarulex and trastuzumab deruxtecan
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with advanced HER2-positive or HER2-low breast cancer and other solid tumors.
- What could go wrong
- This is a very early Phase 1 trial with only 36 participants. The main goal is safety and dosing, not proof of effectiveness. Side effects from the drug combination could be significant, and many early-stage cancer trials do not lead to approved treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a tracer that hunts unstable iron light up hidden tumors?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk